The Conjugate
Vaccines Market Insights And Analysis By
Type (Haemophilus B, Monovalent, Multivalent, And Others), Indication
(Influenza, Pneumococcal, Meningococcal, And Others), End Users (Pediatrics And
Adults) - Forecast Till 2030
The global conjugate vaccines market is
analyzed in detail in the latest market research report from Market Research
Future (MRFR). The report studies the global conjugate vaccines market’s
historical growth trajectory in order to provide pointers as to the major
drivers and restraints affecting the market’s growth prospects and derive
market growth markers that can indicate the market’s future growth trajectory
over the forecast period. The global conjugate vaccines market is expected to
exhibit a robust 9.90% CAGR over the forecast period, according to MRFR.
Conjugate vaccines are vaccines containing
two antigens, one strong and one weak. The stronger antigen is generally made
from proteins and is attached to a weaker polysaccharide antigen to form
conjugate vaccines. Conjugate vaccines are used to counter diseases whose
associated pathogens do not elicit a significant response from the human immune
system on their own. As a result, a stronger antigen is attached to the weaker
pathogen to make it more prominent and to elicit a stronger response from the
immune system. The first conjugate vaccine was developed in response to the
outbreak of meningitis, which still remains among the top targeted diseases in
the conjugate vaccines market.
The growing government support for
mass-scale vaccinations for disease eradication is likely to remain the prime
driver for the global conjugate vaccines market over the forecast period.
Vaccination has taken on a key role in eliminating diseases such as meningitis,
which can become a serious health problem given the right conditions. The
growing support for further advancement in vaccine research and development is
also likely to be a major driver for the global conjugate vaccines market over
the forecast period. Considerable growth in vaccine development efforts from
major market players is likely to be a major driver for the conjugate vaccines
market over the forecast period.
Segmentation:
The conjugate
market trends is segmented on the basis of type, indication, end user, and
region.
On the basis of type, the global
conjugate vaccine market is segmented into haemophilus B, monovalent,
multivalent, and others.
On the basis of indication, the
conjugate vaccines market is segmented into influenza, pneumococcal,
meningococcal, and others. Influenza dominates the global conjugate vaccines
market with a 35% share, however, pneumococcal and meningococcal vaccines are
also likely to take up a considerable share of the global conjugate vaccines
market over the forecast period.
On the basis of end users, the
market is segmented into pediatrics and adults.
Regional
Analysis:
The global conjugate vaccines market
is segmented into Americas, Europe, Asia Pacific, and the Middle East and
Africa. The Americas dominates the global conjugate vaccines market due to the
growing demand for wide-scale disease eradication through vaccines and the
growing vaccine research environment in advanced countries such as the U.S. and
Canada. The growing government support to vaccination and vaccine development
in this region, along with the presence of a strong and advanced biotechnology
sector in the region, is also likely to be a major driver for the conjugate
vaccines market over the forecast period.
Europe follows the Americas region
in terms of its share in the global conjugate vaccines market and is likely to
remain in a leading position through the forecast period due to the growing
awareness about vaccines in Europe and the growing demand for developing
cost-efficient, effective formulations of vaccines. The strong presence of the
medical biotechnology sector in the region is also likely
to be a major driver for the conjugate vaccines market in Europe.
Asia Pacific follows Europe in the
global conjugate vaccines market and is likely to hold a reasonable share in
the global market over the forecast period due to the growing awareness about
the importance of vaccination in countries such as China and India. The growing
population of this region is likely to drive the conjugate vaccines market in
Asia Pacific over the forecast period.
Competitive
Analysis:
Leading players in the global
conjugate vaccine market include GSK plc, Fablife, Sanofi Pasteur SA, Sinovac
Biotech Ltd., GreenSignal Bio Pharma Limited, Bavarian Nordic, Taj
Pharmaceuticals Limited, IDT Biologics, Pfizer, SutroVax Inc., and Merck &
Co. Inc.
Industry
Updates:
In March 2019, Pfizer initiated
three phase III trials on its new 20-valent pneumococcal conjugate vaccine.
About
Market Research Future:
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street, 5Th Floor,
New
York, New York 10013
United
States of America
+1 628
258 0071
Email:
sales@marketresearchfuture.com
Comments
Post a Comment